CompletedPhase 4

Effect of Different Ovarian Stimulation Protocols on Endometrial Receptivity

Portugal24 participantsStarted 2020-01-29

Plain-language summary

This study will assess the change in endometrial gene expression signature on the day of embryo transfer according to the type of exogenous gonadotropins administered.

Who can participate

Age range18 Years – 42 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Informed consent form (ICF) dated and signed.
✓. Age: ≥18 and ≤42 years old.
✓. AFC \<20.
✓. AMH \<2.5 ng/mL, performed in the 12 months prior to inclusion.
✓. Body Mass Index (BMI): ≥18.5 Kg/m2 and \<30 Kg/m2.
✓. Weight: ≥50 kg and \<80 kg.
✓. First or second ART cycle (with pregnancy wish and planned for single blastocyst transfer) at the study site, or fertility preservation cycle.
✓. Regular menstrual cycles (between 22 and 35 days).

Exclusion criteria

✕. Simultaneous participation in another clinical study.
✕. Previous history of poor ovarian response (\<4 oocytes retrieved) with a maximal dose of OS (≥300 IU/day) or OHSS, regardless of gonadotropin dose.
✕. Known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial tuberculosis).
✕. Repeated miscarriages (\>2 previous biochemical pregnancies or \>2 spontaneous miscarriages).
✕. Recurrent implantation failure (\>3 failed cycles with good quality embryos).
✕. Polycystic ovary syndrome (PCOS).
✕. Tumours of the ovary, breast, uterus, pituitary or hypothalamus.
✕. Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.

What they're measuring

Endometrial gene expression signature on the day of embryo transfer

Timeframe: 7 days after the last day of ovarian stimulation

Trial details

NCT IDNCT03755973

SponsorInstituto Valenciano de Infertilidade de Lisboa

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2023-05-22

View on ClinicalTrials.gov More Infertility, Female trials